Skip to main content
. 2011 Aug;165(2):217–223. doi: 10.1530/EJE-11-0286

Table 4.

Primary invasive cancer incidence in GH-treated and non GH-treated patients from the USA. SIRs were calculated using SEER data (24).

Treatment group Observed cases Expected cases SIR (95% CI)
GH-treated (n=3165) 71 75.79 0.94 (0.73–1.18)
Non GH-treated (n=631) 27 23.28 1.16 (0.76–1.69)

CI, confidence interval; SIR, standardized incidence ratio.